Dengue challenge trial: prior antibodies decide whether a second infection is tamed or amplified
- Forty-five healthy adults with differing dengue histories received a live attenuated virus of a different serotype in a controlled phase 1 challenge.
- Prior exposure boosted viral load and immune responses, yet baseline antibodies that enhanced infection in vitro predicted the weakest control and fading T and B cell memory.
- Antibodies against NS1 across serotypes, or strong neutralizing and T cell immunity at baseline, tracked with early interferon signaling and little replication, pointing vaccine design toward NS1.
💡 Points Based on the abstract
Any dengue vaccine program now has to treat baseline serostatus as a covariate, not a footnote: in vitro enhancing antibodies predicting poor control in humans is the readout we've lacked. NS1 antibodies tracking with suppressed replication is attractive, but with 45 volunteers and one attenuated strain, I'd want it validated as a true correlate before designing around it.